The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

The discussion follows questions councilors had during the last needle exchange workshop earlier this month about how to ...

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across ...

If you're stocking up on Thanksgiving meal must-haves, this one can't be missed. Add it to your Amazon cart now.

Orforglipron, a GLP-1 drug taken as a pill, achieved positive results in people with obesity and type 2 diabetes, although it ...

In mice with type 1 diabetes, a topical dose of OP-I was smeared onto the skin. Blood glucose levels fell to a normal range ...

With the big day just around the bend, we asked a supersized panel of as-seen-on-TV chefs and other foodies with local ...

A groundbreaking polymer-based skin cream shows promise in replacing painful daily insulin injections for diabetes management ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing ...

The MarketWatch News Department was not involved in the creation of this content.-- Omlyclo(TM) (omalizumab) is the first and only omalizumab biosimilar approved in Europe -- Omly ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.